Introduction
============

Levofloxacin, which is the active isomer of ofloxacin, is a third-generation fluoroquinolone antibiotic that has a broad antibacterial spectrum and is widely used. Pooled safety data for levofloxacin (n=7,537) suggest that the most common adverse drug reactions leading to discontinuation of the medication are gastrointestinal adverse reactions (1.4%), nausea (0.6%), vomiting (0.4%), dizziness (0.3%), and headache (0.2%) ([@B1]). The safety and efficacy of levofloxacin have been well documented, and central nervous system (CNS) toxicity is low, occurring in just 1 out of every 6 million prescriptions ([@B2], [@B3]).

We herein report a case of acute psychotic symptoms with severe hyperventilation after a patient took one tablet of levofloxacin. This is the first report describing hyperventilation as an adverse effect of quinolones.

Case Report
===========

A 64-year-old woman had increased urinary frequency and experienced an uncomfortable feeling while urinating for several days. A urologist diagnosed her with cystitis and prescribed levofloxacin. Two hours after taking a single 500 mg tablet of levofloxacin without any other medicine, the patient became restless and confused. She visited the clinic again and was referred to our hospital for a further examination and treatment.

The patient had undergone mastectomy for right breast cancer and received chemotherapy seven years earlier. She had been subsequently followed up with no signs of recurrence. She had no history of a confusional state and no documented disorders of the central nervous system. She was a non-smoker and did not have any history of alcohol misuse or antipsychotic drug use.

On a physical examination, the patient\'s temperature was 37.8 °C, and she had a blood pressure of 115/56 mmHg, a heart rate of 114 beats per min, and a respiratory rate of 34 breaths per min. She was confused and disoriented and was becoming agitated. We observed bilateral mild muscular rigidity in the upper and lower limbs and involuntary movement characterized by dyskinesia. She had no episodes of autonomic instability such as hyperhidrosis or convulsions. The patient reported visual hallucinations, saying "a baby boy is lying next to me" and repeating many times that "he is going to die".

Laboratory examinations determined a white blood cell count of 8,300/μL, hematocrit of 32.6%, platelet count of 30.7×10^4^/μL, serum creatinine level of 0.85 mg/dL, blood urea nitrogen (BUN) level of 16.4 mg/dL, sodium level of 140 mEq/L, potassium level of 2.7 mEq/L, aspartate transaminase level of 53 U/L, alanine aminotransferase level of 42 U/L, lactate dehydrogenase level of 275 U/L, C-reactive protein level of 20.1 mg/dL, thyroid stimulating hormone level of 2.66 μIU/mL, and NH~3~ level of 20 μg/dL. An assessment of the patient\'s blood gas revealed a pH of 7.82, carbon dioxide partial pressure (pCO~2~) of 10.3 mmHg, partial pressure of oxygen (pO~2~) of 165 mmHg, and HCO~3~ of 17.6 mmol/L. Anti N-methyl-D-aspartate (NMDA) receptor antibody was not detected. Chest X-ray showed no active lesions, and head computed tomography (CT) and brain magnetic resonance imaging (MRI) showed no abnormal findings. Whole-body CT and MRI to assess the abdomen and pelvis revealed no active or tumorous lesions. A cerebrospinal fluid (CSF) analysis provided a white cell count of 1 cell/μL, with glucose and protein levels of 66 mmol/L and 14.2 g/L, respectively. An electroencephalogram (EEG) on the second day showed intermittent rhythmic delta activity with background beta activity but no epileptiform discharge ([Figure](#g001){ref-type="fig"}).

![An electroencephalogram on the second day showed intermittent rhythmic delta activity with background beta activity but no epileptiform discharge.](1349-7235-58-1495-g001){#g001}

The patient presented with hyperventilation with a respiratory rate of approximately 90 breaths per min and exacerbation of severe respiratory alkalosis. Her hyperventilation improved gradually on the third day of admission following the injection of 10 mg haloperidol in addition to 10 mg diazepam.

At admission, after the patient discontinued levofloxacin, meningoencephalitis was suspected, so she was treated with antibiotic medication (vancomycin, ceftriaxone, ampicillin, and acyclovir). On the fourth day, she was able to say her name but remained drowsy and showed coarse tremor in all her limbs. Since these symptoms were improving, medication was stopped on the fourth day of admission. On the fifth day, the patient became mostly alert and oriented but still had impaired attention, with a Mini-Mental State Examination score of 25. She was discharged after 17 days without any neurological deficits.

Discussion
==========

Although medications are commonly considered a reversible cause of encephalopathy, antibiotics are underrecognized in the etiology of the condition. In this case, the temporal relationship between the patient\'s consumption of levofloxacin and the acute alteration in her level of consciousness suggested that levofloxacin was the precipitant of the psychotic symptoms. Bhattacharyya et al. ([@B4]) conducted a review and proposed the concept of antibiotic-associated encephalopathy (AAE). They classified AAE into three types, with quinolones belonging to Type 2 AAE, which is characterized more by predominant psychotic symptoms than seizures or myoclonus. AAE arises within days of antibiotic administration and resolves after antibiotic discontinuation. Due to the marked improvement observed on discontinuing levofloxacin in this case, we diagnosed the condition as levofloxacin-associated encephalopathy, and the original cause of the fever was presumably cystitis.

To our knowledge, there have been 12 case reports, including the present one, on levofloxacin-associated encephalopathy ([@B5]-[@B15]) ([Table](#t001){ref-type="table"}). The patients ranged in age from 13-83 years (mean, 46 years old). The dose of levofloxacin administered ranged from 300 to 500 mg/day, and all patients showed symptoms of psychosis, while 2 presented with extra pyramidal signs. An EEG was performed in just four patients, with only one patient other than our own showing slow background activity and none showing epileptiform discharge. Head CT and brain MRI as well as CSF examinations revealed no specific findings. Psychotic symptoms occurred between 2 hours and 3 days after the oral intake of levofloxacin. In most cases, prompt discontinuation of levofloxacin let to improvement within 48 hours of onset.

###### 

Previously Reported Cases of Levofloxacin-associated Encephalopathy.

  Case no.   RN               Age   Sex   Underlying disease                             Reason for prescription         Renal failure   Daily dose        Time to symptom onset   Recovery time after discontinuation   EEG                                                                  MRI/CT                CSF   Other symptoms                                         Prognosis
  ---------- ---------------- ----- ----- ---------------------------------------------- ------------------------------- --------------- ----------------- ----------------------- ------------------------------------- -------------------------------------------------------------------- --------------------- ----- ------------------------------------------------------ -----------
  1          5                67    M     Gall bladder cancer and alcohol dependence     Flu                             N               300 g/day p.o.    4 days                  1 day                                 ND                                                                   ND                    ND    Involuntary movements and convulsions                  Good
  2          6                73    M     NP                                             Pneumonia                       N               500 mg/day p.o.   2 days                  2 days                                ND                                                                   No specific finding   ND    NP                                                     Good
  3          7                50    M     Diabetes mellitus and hypertension             Pneumonia, UTI and cellulitis   N               500 mg/day p.o.   3 days                  2 days                                ND                                                                   ND                    WNL   NP                                                     Good
  4          8                42    F     NP                                             Sinusitis and UTI               N               500 mg/day p.o.   2 days                  2 days                                ND                                                                   ND                    WNL   NP                                                     Good
  5          9                83    M     Coronary bypass surgery and breast carcinoma   Pneumonia                       Y               500 mg/day IV     3 days                  2 days                                Slow background activity                                             ND                    WNL   Extrapyramidal syndrome                                Good
  6          10               55    M     Hypertension and inguinal hernia               Pneumonia                       Y               500 mg/day IV     6 days                  2 days                                WNL                                                                  WNL                   ND    NP                                                     Good
  7          11               13    F     NP                                             Acute bronchitis                N               500 mg/day p.o.   2 h                     4 days                                WNL                                                                  WNL                   WNL   NP                                                     Good
  8          12               38    M     Multiple sclerosis and hepatitis C             Pneumonia                       N               500 mg/day p.o.   3 days                  1 day                                 ND                                                                   ND                    ND    NP                                                     Good
  9          13               28    M     NP                                             Pneumonia and UTI               N               500 mg/day p.o.   3 days                  2 days                                ND                                                                   ND                    WNL   NP                                                     Good
  10         14               17    M     Synovial sarcoma with metastasis               Pneumonia                       ND              500 mg/day IV     35 min                  4 h                                   ND                                                                   ND                    ND    NP                                                     Good
  11         15               22    F     NP                                             UTI                             N               500 mg/day p.o.   3 h                     3 days                                ND                                                                   ND                    ND    NP                                                     Good
  12         (Present case)   64    F     Breast cancer                                  Cystitis                        N               500 mg/day p.o.   2 h                     4 days                                Intermittent rhythmic delta activity with background beta activity   WNL                   WNL   Hyperventilation, involuntary movement, and rigidity   Good

R.N: reference number, M: male, F: female, NP: none present, UTI: urinary tract infection, IV: intravenous, N: no, Y: yes, ND: not described, p.o.: per os, EEG: electroencephalogram, MRI: magnetic resonance imaging, CT: computed tomographic scanning, WNL: within normal limits, CSF: cerebrospinal fluid

Similar to the findings in 1 previously reported case ([@B11]), psychotic symptoms appeared 2 hours after taking a 500 mg tablet of levofloxacin in our case and improved within 36 hours after discontinuation of the drug. Levofloxacin is rapidly absorbed from the gastrointestinal tract, with the time to maximum plasma concentrations (T max) ranging from 0.8 to 2.4 hours after the administration of 50-1,000 mg with or without food ([@B16]). Therefore, while the time to the onset of symptoms was shorter in this case than in previously reported cases, that psychosis developed just 2 hours after the oral intake is not unexpected. According to previous reports, the mean age of patients with an acute onset (not including our patient) was 17.3 years, whereas the mean age of the patients with a relatively late onset was 54.5 years. Although the acute development is more frequent in young patients than in older ones, this might be due to the blood-brain barrier influencing the concentrations of levofloxacin in the brain tissue to a variable degree ([@B17]). Additional case reports will be required to confirm the etiology associated with a more acute onset.

Previous studies have suggested that the pathophysiology of levofloxacin-associated encephalopathy is associated with a disturbance of gamma-aminobutyric acid-ergic (GABAergic) interneurons. Quinolones affect the central nervous system mainly by inhibiting GABA receptor binding, which is concentration-dependent ([@B18]). Some animal models suggest that the onset of psychosis involves dysfunction of GABAergic interneurons, leading to excessive cortical glutamatergic activity, which in turn mediates subcortical dopamine activity ([@B19]).

In the present case, in addition to psychotic features, the patient experienced prominent ventilation disturbance. This is the first report describing hyperventilation as an adverse effect of quinolones. Hyperventilation persisted for approximately 36 hours with respiratory alkalosis, with the pH increasing to 7.82 on blood gas examinations. The major cause of central neurogenic hyperventilation is infiltrative tumors involving the brainstem ([@B20]). However, there are a few cases of hyperventilation caused by anti-NMDA receptor encephalitis ([@B21], [@B22]). An antibody-mediated decrease in NMDA receptors predominantly inactivates GABAergic neurons and leads to many clinical features of the disorder ([@B23]).

The generation of ventilatory rhythm via the brainstem derives from a complex interplay between several brainstem sites. The NMDA receptor system may play an excitatory role in several steps leading both to the augmentation and termination of inspiration ([@B24]). As in cases of anti-NMDA receptor encephalitis, impaired GABAergic interneurons may lead to hyperventilation via dysfunction of the brainstem respiratory network. In addition, other symptoms, including extrapyramidal signs, such as rigidity and dyskinesia, can also be caused by the disinhibition of dopaminergic and glutaminergic neurons arising from the same neuronal network disturbance as in anti-NMDA receptor encephalitis. Both hyper- and hypoventilation can also be explained based on a functional neurotransmitter imbalance which is predominantly characterized by the presence of hypo-GABAergic tone and glutamatergic hyperactivity ([@B23]). Therefore, it may be important to identify altered respiratory rhythm patterns in cases of levofloxacin-associated encephalopathy.

Conclusion
----------

Levofloxacin-associated encephalopathy characterized by psychotic features is a rare adverse event that can occur within two hours after taking a single tablet. In addition, the disturbance of GABAergic interneurons by levofloxacin may lead to hyperventilation via dysfunction of the brainstem respiratory network. Physicians should be aware of hyperventilation as an additional serious symptom of AAE in acute settings.
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